Metagen Therapeutics

Metagen Therapeutics (MGTx) is a clinical-stage biotechnology company headquartered in Tsuruoka City, Yamagata, Japan, pioneering next-generation medical treatments through gut microbiome science. The company operates across two primary divisions — drug discovery and medical services — with a focus on Fecal Microbiota Transplantation (FMT) therapies, including its lead drug candidate MGT-006, which entered a Phase 1/2 clinical trial for ulcerative colitis across Japan and the United States in 2026. MGTx has raised approximately JPY 6.6 billion (roughly $43M USD) in total funding and has established a gut microbiota donor platform in partnership with J-Kinso Bank to secure high-quality stool donations as the essential starting material for its microbiome therapies. The company is affiliated with Metagen, Inc. and backed by investors including Global Brain.